| Identification | Back Directory | [Name]
NBD-556 | [CAS]
333353-44-9 | [Synonyms]
NBD-556
NBD-556;NBD 556; NBD556
N-(4-Chlorophenyl)-N'-(2,2,6,6-tetramethylpiperidin-4-yl)oxalamide
N1-(4-Chlorophenyl)-N2-(2,2,6,6-tetramethylpiperidin-4-yl)oxalamide
N1-(4-Chlorophenyl)-N2-(2,2,6,6-tetramethyl-4-piperidinyl)-ethanediamide
Ethanediamide, N1-(4-chlorophenyl)-N2-(2,2,6,6-tetramethyl-4-piperidinyl)- | [Molecular Formula]
C17H24ClN3O2 | [MDL Number]
MFCD00469538 | [MOL File]
333353-44-9.mol | [Molecular Weight]
337.844 |
| Safety Data | Back Directory | [Hazard Codes ]
T | [Risk Statements ]
25 | [Safety Statements ]
45 | [RIDADR ]
UN 2811 6.1 / PGIII | [WGK Germany ]
3 | [HS Code ]
2933.39.9200 | [HazardClass ]
6.1 | [PackingGroup ]
III |
| Hazard Information | Back Directory | [Uses]
NBD-556 is a N-phenyl-N'-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamide analog, a novel class of human immunodeficiency virus type 1 (HIV-1) entry inhibitors that block the gp120-CD4 interaction. | [Biological Activity]
the entry of hiv-1 into host cells is mediated by the binding of the surface subunit gp120 to the host cell receptor cd4. nbd-556 is a novel class of human immunodeficiency virus type 1 (hiv-1) entry inhibitor that block the gp120–cd4 interaction with drug-like properties. | [in vitro]
a systematic study showed that nbd-556 and nbd-557 target viral entry by inhibiting the binding of hiv-1 envelope glycoprotein gp120 to the cellular receptor cd4 but did not inhibit reverse transcriptase, protease, or integrase, demonstrating that they do not target the later stages of the hiv-1 life cycle to inhibit hiv-1 infection. nbd-556 and nbd-557 were also active against hiv-1 laboratory-adapted strains including an azt-resistant strain and hiv-1 primary isolates, showing that these compounds can potentially be further modified to become potent hiv-1 entry inhibitors [1]. | [IC 50]
nbd-556 inhibited cell–cell fusion between h9/hiv-1iiib and mt-2 (ic50 ~3 μm) | [References]
[1] zhao, q. , l. ma, s. jiang, h. lu, s. liu, y. he, n. strick, n. neamati, and a. k. debnath. 2005. identification of n-phenyl-n′-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamides as a new class of hiv-1 entry inhibitors that prevent gp120 binding to cd4. virology 339:213-225. |
|
| Company Name: |
TCI Europe
|
| Tel: |
320-37350700 |
| Website: |
https://www.tcichemicals.com/de/de/index.html |
| Company Name: |
TCI AMERICA
|
| Tel: |
800-4238616 |
| Website: |
https://www.tcichemicals.com/en/us/index.html |
| Company Name: |
SPIRO PHARMA
|
| Tel: |
|
| Website: |
www.spiropharma.com.cn |
| Company Name: |
BOC Sciences
|
| Tel: |
16314854226 |
| Website: |
www.bocsci.com |
|